SCHEMBL255097

SCHEMBL255097

CN1CC2CCCC2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13924060 1.00
SCHEMBL20031091 1.00
SCHEMBL13201847 1.00
SCHEMBL14589071 0.93 ALDH1A1 (0.44)
SCHEMBL26957504 0.93 ALDH1A1 (0.44)
SCHEMBL256347 0.93 ALDH1A1 (0.44)
SCHEMBL26957962 0.93 ALDH1A1 (0.44)
SCHEMBL26484979 0.91 ALDH1A1 (0.44)
SCHEMBL14407323 0.90 ALDH1A1 (0.41)
SCHEMBL21440591 0.90 ALDH1A1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118993979-A Synthesis method of gliclazide intermediate 南京介子连续流科技有限公司 2024-11-22 CN disclosed
US-20240239812-A1 MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS INHIBITORS OF MCL-1 JANSSEN PHARMACEUTICA NV (BE) 2024-07-18 US disclosed
US-20240208945-A1 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES MEDSHINE DISCOVERY INC. (CN) 2024-06-27 US disclosed
US-20240150324-A1 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV ASSEMBLY BIOSCIENCES, INC. 2024-05-09 US disclosed
WO-2024091409-A1 TRICYCLIC DERIVATIVES AS KRAS INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
US-20240067660-A1 MACROCYCLIC SPIROCYCLE DERIVATIVES AS MCL-1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-02-29 US disclosed
US-20240025887-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF SINAI HEALTH SYSTEM (CA) 2024-01-25 US disclosed
US-20230339851-A1 CXCR6 SULFONAMIDE COMPOUNDS CHEMOCENTRYX, INC. 2023-10-26 US disclosed
WO-2023192430-A1 COMPOUNDS FOR TREATING PSYCHOSTIMULANT MISUSE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORTED (US) 2023-10-05 WO disclosed
US-20230312571-A1 RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) 2023-10-05 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213356-A1 Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-13 US disclosed
US-20070213356-A1 Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-13 US disclosed
US-20070191395-A1 Heterocyclic compounds having antifungal activity DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
US-20070191395-A1 Heterocyclic compounds having antifungal activity DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
EP-1784375-A1 METHOD FOR THE PRODUCTION OF FORMIC ACID BASF AKTIENGESELLSCHAFT (DE) 2007-05-16 EP disclosed
EP-1749821-A1 Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-02-07 EP disclosed
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2007-02-01 US disclosed
WO-2007009697-A1 QUATERNARY AMMONIUM SALTS OF SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-25 WO disclosed
WO-2006021411-A1 METHOD FOR THE PRODUCTION OF FORMIC ACID BASF AKTIENGESELLSCHAFT (DE) 2006-03-02 WO disclosed